Indian companies have secured 51 final ANDA approvals from US FDA during the first quarter of January-March 2018, out of total 112 approvals. This worked out to 45 per cent of total approvals in the first quarter. During the same period last year, Indian companies had grabbed 55 final ANDA approvals out of 171 approved by US FDA. Further, Indian companies received 6 tentative approvals from aggregate 23 tentative approvals in the first quarter of Jan-March 2018. The overall approvals declined to 112 ANDAs from 171 ANDAs in the same quarter of last year and 23 tentative approvals as compared to 43 tentative approvals.
Aurobindo Pharma has received the highest numbers of ANDA approvals among the Indian companies during the first quarter of 2018. It received 11 final ANDA approvals followed by Strides Shasun 6, Lupin 5, Cipla and Zydus Pharma 4 each, Dr Reddy’s Laboratories, Hetero Labs and Taro Pharma 3 each. Macleods Pharma and Vivimed Global received 2 approval each. Alkem Laboratories, Gland Pharma, Glenmark Pharma, Granules India, Jubilant Life, Laurus Labs, Micro Labs and Torrent Pharma received one ANDA approval each in the first quarter.
For the full year ended December 2017, Indian companies obtained 304 ANDA approvals out of 846 approvals by US FDA and 61 tentative approvals from 172 approvals. Among the Indian companies Zydus Pharma USA, received highest approvals of 66 ANDAs in 2017 followed by Aurobindo at 51 and Glenmark Pharma at 18.
EMA Opens Consultation on GMP Non-Compliance Statement. Click below to open the url:
The draft guidance on “Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials” has issued today and is available at:
This draft guidance discusses the ethical and scientific issues when considering the inclusion of pregnant women in clinical trials of drugs and biological products. This draft guidance is intended to advance scientific research in pregnant women, and discusses issues that should be considered within the framework of human subject protection regulations.
To prevent the indiscriminate sale of topical preparations containing steroids and antibiotics without prescription, the Health Ministry has banned over-the-counter sale of around 14 such creams.
In a notification issued on March 23, the ministry has put 14 steroid-based creams and ointments under the Schedule H category by making amendments to certain Drugs and Cosmetics Rules, 1945.
The decision was taken following consultation with the Drugs Technical Advisory Board (DTAB) which had recommended a ban on the sale of such creams without prescription and had also submitted their recommendations to the Central Drugs Standards Control Organisation (CDSCO).
The move come after dermatologists complained that pharmaceutical companies were selling steroid- based creams and ointments to patients who use them without medical guidance.
The revised rules will apply to skin creams that contain steroids or other prescription drugs and not for ordinary face-cleansing and moisturisers.
The creams which have been banned are alclometasone, beclomethasone, desonide, desoximetasone and flucinonide among others.
Subsequent to Indian Pharmacopoeia Commission (IPC) having been awarded the status of “Observer” for participation in the activities of the European Directorate for the Quality of Medicine and Healthcare (EDQM), IPC has announced to organize the “IPC-EDQM Symposium on Drug Standards and Regulatory Updates” from April 26 & 27, 2018 in Mumbai.
The programme shall offer a unique opportunity for the organizers to present jointly their work and roles in taking forward the activities through active participation of stakeholders which include professionals from pharma industry, API manufacturers, associations, academicians, individuals, regulators, etc.
The participants will have the opportunity to hear key speakers from IPC, EDQM and regulatory bodies and attend interactive sessions.
FDA suggests that adherence to the data integrity is must to ensure the cGMP compliance. GMP is a system for ensuring that products are consistently produced and controlled according to quality standards.
A+ a- 0
The data integrity issues have been frontrunners for the USFDA to hammer pharma companies. The data integrity-related CGMP violations have led to several regulatory actions, including warning letters, import alerts, and consent decrees. A few years ago, Ranbaxy signed a consent decree with USFDA and also paid $500mn in civil and criminal fines.
Plants of Wockhardt, IPCA laboratories remain under the warning letter/import alerts for long now. Dr. Reddy had received a warning letter in 2015 over data integrity issues, along with others. Over the last two years, Indian companies like USV, Hetero and Sri Krishna Pharmaceuticals (all unlisted), Agila Specialties (Mylan’s subsidiary), etc. have received warning letters over data integrity, which USFDA gives a very high importance.
Recently, Sun Pharma, Aurobindo, Biocon, etc. received form 483 observations, but there was no data integrity related observations, hence stocks did not tank heavily. In case of Sun Pharma, the stock moved up. This makes it interesting to understand data integrity, from the eyes of USFDA.
USFDA suggests that data integrity refers to the completeness, consistency, and accuracy of data, which should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate. USFDA suggests that adherence to the data integrity is must to ensure the cGMP compliance. GMP is a system for ensuring that products are consistently produced and controlled according to quality standards.
FDA’s minimum data integrity requirements are:
Data should be secure from alteration, inadvertent erasures, or loss. Backup data should be exact and complete.
Data should be stored to prevent deterioration or loss.
Certain activities should be documented at the time of performance and that laboratory controls should be scientifically sound.
The records should be retained as original records, true copies, or other accurate reproductions of the original records.
FDA requires data to record complete information, a complete record of all data from all the tests performed, and no test or data should be failed to record.
FDA also requires metadata to be stored throughout the record’s retention period.
Other guidance that USFDA suggests when it comes to data integrity includes:
The data to be auditable for reconstruction of the past events relating to the creation, modification, or deletion of the records.
The manufacturing companies should enable appropriate controls over the data/records so that change in the records can only be made only by authorized personnel restricting of the alteration of the records.
The system administrator role for computers (having rights to alter files and settings) be assigned to personnel independent from those who are responsible for recording the content.
The systems controls, including documentation controls, should be designed to follow CGMP to assure product quality.
Companies must keep the incomplete or the erroneous forms as part of the permanent record along with written justification for their replacement.
All changes in the critical data to be audit trailed.
The processes should be designed so that quality data to be created and maintained cannot be modified.
USFDA prohibits followings:
Recording of the data on pieces of paper that can be discarded.
Storing of the data in temporary memory.
Sampling and testing with the goal of achieving a specific result or to overcome an unacceptable result as this is not as per the CGMP standards.
Use of actual samples to perform system suitability (system suitability tests should be done by using written procedures and data should be recorded for scientific justification for exclusion).
USFDA suggests that drug shall be deemed adulterated if the methods or facilities or controls used to manufacture, process, pack, or hold the drug does not conform to adherence to the current good manufacturing practice. The adherence to the cGMP is required to assure that the drug has safety, identity and strength that meets the on the quality and purity characteristics.
(Source for this is USFDA website: Data Integrity and Compliance With CGMP Guidance for Industry)
Q1A (R2) – Stability Testing of New Drug Substances and Products
Q1 B – Stability Testing : Photo Stability Testing of New Drug Substances and Products
Q1C – Stability Testing for New Dosage Forms
Q1D – Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
Q1E – Evaluation of Stability Data
Q1F – Stability Data Package for Registration Application in Climatic Zones III and IV
Q2 (R1) – Validation of Analytical Procedures : Text and Methodology
Q3A (R2) – Impurities in New Drug Substances
Q3B (R2) – Impurities in New Drug Products
Q3C (R5) – Impurities : Guideline for Residual Solvents
Q3D – Impurities : Guideline for Elemental Impurities
Q4 – Pharmacopoeias
Q4A – Pharmacopoeial Harmonisation
Q4B – Evaluation and Recommendation of Pharmacopoeial Text for use in the ICH Regions
Q4B Annex 1(R1) – Residue on Ignition /Sulphated Ash General Chapter
Q4B Annex 2(R1) – Test for Extractable Volume of Parenteral Preparation General Chapter
Q4B – Annex 3(R1) – Test for Particulate Contamination : Sub-Visibal Particales General Chapter
Q4B – Annex 4A(R1) – Microbiological Examination of Non-Sterile Products : Microbial Enumeration Tests General Chapter
Q4B – Annex 4B(R1) – Microbiological Examination of Non-Sterile Products : Test for Specified Micro-Organism General Chapter
Q4B – Annex 4C(R1) – Microbiological Examination of Non-Sterile Products : Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical use General Chapter
Q4B – Annex 5(R1) – Disintegration Test General Chapter
Q4B Annex 6 (R1) – Uniformity of Dosage Units General Chapter
Q4B Annex 7(R2) – Dissolution Test General Chapter
Q4B Annex 8(R1) – Stability Test General Chapter
Q4B Annex 9(R1) – Tablet Friability General Chapter
Q4B Annex 10(R1) – Polyacrylamide Gel Electrophoresis General Chapter
Q4B Annex 11 – Capillary Electrophoresis General Chapter
Q4B Annex 12 – Analytical Sieving General Chapter
Q4B Annex 13 – Bulk Density and Tapped Density of Powders General Chapter
Q4B Annex 14 – Bacterial Endotoxin Test General Chapter
Q5A(R1) – Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
Q5B – Quality of Biotechnology Products :
Q5C – Quality of Biotechnology Products :Quality of Biotechnological
Q5D – Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products
Q5E – Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process
Q6A – Specifications : Test Procedure and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
Q6B – Specifications : Test Procedure and Acceptance Criteria for Biotechnological/Biological
Q7 – Good Manufacturing Guide for Active Pharmaceutical Ingredients
Q8(R2) – Pharmaceutical Development
Q9 – Quality Risk Management
Q10 – Pharmaceutical Quality System
Q11 – Development and Manufacture of Drug Substances (Chemical Entities Biotechnological/Biological Entities)
Q12 – Life Cycle Management